Summary & Overview
CPT 0530U: LiquidHallmark® ctDNA NGS Assay with Interpretive Report
CPT code 0530U designates LiquidHallmark®, a proprietary next-generation sequencing (NGS) assay performed by Lucence Health Inc. that analyzes circulating tumor DNA (ctDNA) in plasma to detect mutations in 77 genes, identify eight gene fusions, and evaluate microsatellite instability and tumor mutation burden, accompanied by an interpretive report with therapy recommendations. As a PLA code, 0530U is specific to a single manufacturer’s test and is used nationally to capture use of this distinct genomic assay in oncology care.
Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical utility and coding context, typical sites of service, and payer coverage considerations. The publication summarizes common modifiers used with laboratory services, highlights where data was available or not, and outlines what benchmarks and policy updates to watch for with PLA codes.
The analysis provides clinical context for when a ctDNA NGS assay with comprehensive genomic profiling and interpretive guidance is requested, and it identifies areas where payers commonly apply medical necessity criteria or prior authorization for advanced molecular tests. Data not available in the input is noted where applicable; the content focuses on national implications rather than state-specific policies.
Billing Code Overview
CPT code 0530U is a Proprietary Laboratory Analyses (PLA) code that applies exclusively to the LiquidHallmark® test from Lucence Health Inc. The test analyzes circulating tumor DNA (ctDNA) in plasma using next-generation sequencing (NGS) to detect mutations across 77 genes, identify eight gene fusions, and assess microsatellite instability (MSI) and tumor mutation burden (TMB). The service includes an interpretive report with therapy recommendations based on the genomic findings.
Service type: Laboratory — circulating tumor DNA (ctDNA) NGS assay with genomic interpretation and therapeutic guidance
Typical site of service: Clinical laboratory or independent diagnostic testing facility (specimen collected in outpatient or hospital settings and processed in a central lab)
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with a history of metastatic non–small cell lung cancer (NSCLC) presents for evaluation after progression on first-line targeted therapy. The oncology team orders a plasma-based circulating tumor DNA (ctDNA) assay, LiquidHallmark® (0530U), to identify actionable somatic mutations, gene fusions, microsatellite instability (MSI), and tumor mutation burden (TMB) to guide next-line systemic therapy and clinical trial eligibility. A peripheral blood draw is collected in an appropriate cell-free DNA tube in the outpatient oncology clinic or an ambulatory phlebotomy center. The sample is shipped to Lucence Health Inc. per the manufacturer’s specimen handling instructions. Results include an interpretive report with detected variants, fusion calls, MSI and TMB status, and therapy recommendations that the treating medical oncologist reviews during a follow-up visit or tumor board to inform systemic treatment selection or referral for targeted therapy or immunotherapy.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Default/No modifier — not commonly appended; use when no other modifier applies | Rarely used; report when service has no specific modifier requirement |
22 | Increased procedural services | Use when additional work or complexity was required beyond the typical laboratory analytic and interpretive effort and documentation supports increased work